DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Rilotumumab
Rilotumumab
The Role of Biological Therapy in Metastatic Colorectal Cancer After First-Line Treatment: a Meta-Analysis of Randomised Trials
Targeted and Novel Therapy in Advanced Gastric Cancer Julie H
Therapeutic Targeting of the IGF Axis
Correlation Between Gene Expression of IGF-1R Pathway Markers and Cetuximab Benefit in Metastatic Colorectal Cancer
Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma
The Two Tontti Tudiul Lui Hi Ha Unit
Insulin-Like Growth Factor Receptor Signaling in Tumorigenesis and Drug
Journal of Cancer Metastasis and Treatment
(INN) for Biological and Biotechnological Substances
Ep 3321281 A1
Randomized Phase Ib/II Trial of Rilotumumab Or Ganitumab with Panitumumab Versus Panitumumab Alone in Patients with Wild-Type KRAS Metastatic Colorectal Cancer
Phase Ib/II Study in Metastatic Renal Cell Carcinoma
INN Working Document 05.179 Update 2011
AHRQ Healthcare Horizon Scanning System – Status Updates
INN Working Document 05.179 Update December 2010
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
WO 2017/176762 Al 12 October 2017 (12.10.2017) P O P C T
Targeted Therapies for Gastroesophageal Cancers
Top View
(12) Patent Application Publication (10) Pub. No.: US 2016/0184445 A1 Perroth Et Al
(INN) for Biological and Biotechnological Substances
Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies
Advances in Systemic Therapy for Metastatic Or Advanced Gastric Cancer
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
Exposure-Response Analysis of Rilotumumab in Gastric Cancer: the Role of Tumour MET Expression
Orphan Drug Designations and Approvals List As of 12-02-2013 Governs January 1, 2014
ESMO 2012 Ficlatuzumab PKPD Poster
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer
Targeting the Oncogenic Met Receptor by Antibodies and Gene Therapy
IGF System in Sarcomas: a Crucial Pathway with Many Unknowns to Exploit for Therapy
Anti-IGF-1R Monoclonal Antibody
( 12 ) United States Patent
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): a Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
(12) Patent Application Publication (10) Pub. No.: US 2017/0173267 A1 Ashmead Et Al
Valstybinės Vaistų Kontrolės Tarnybos Prie Lietuvos Respublikos Sveikatos Apsaugos Ministerijos Viršininko Įsakymas
AHRQ Healthcare Horizon Scanning System – Status Updates